Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $20.25.
A number of research firms recently issued reports on FOLD. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Cowen restated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 7th. ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 17th.
Amicus Therapeutics (NASDAQ FOLD) traded up $0.01 during trading hours on Friday, hitting $15.14. 2,491,059 shares of the stock were exchanged, compared to its average volume of 3,528,802. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $2,520.00, a price-to-earnings ratio of -8.27 and a beta of 1.45. Amicus Therapeutics has a twelve month low of $6.22 and a twelve month high of $17.40.
In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the sale, the insider now directly owns 69,184 shares in the company, valued at $940,210.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John F. Crowley sold 65,581 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the sale, the chief executive officer now owns 393,076 shares of the company’s stock, valued at $5,310,456.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 250,390 shares of company stock valued at $3,620,581. 3.40% of the stock is owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $102,000. Birchview Capital LP purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $151,000. Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $154,000. Engineers Gate Manager LP purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $155,000. Finally, Neuberger Berman Group LLC purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $196,000.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/14/amicus-therapeutics-inc-fold-receives-20-25-average-target-price-from-analysts.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.